Is Cologuard Maker Exact Sciences Underestimating Revenue Guidance?

Exact Sciences (EXAS) – Get Exact Sciences Corporation Report reached an important milestone in 2021. Its flagship product, the colon-cancer-screening tool Cologuard, became the first diagnostic test to achieve $1 billion in annual revenue.

That was more revenue than peers Invitae (NVTA) – Get Invitae Corporation ReportSema4 (SMFR) and 23andMe (ME) – Get 23andMe Holding Co. Report generated combined – and it’s only one part of the leader’s overall business.

Management this year expects the growth engine to keep humming along. The midpoint of full-year 2022 revenue guidance exceeds $2 billion, including at least $1.3 billion from Cologuard alone. That would represent year-over-year growth of 20% when covid testing revenue is excluded.


Leave a Reply

Your email address will not be published.

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker